![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, September 04, 2018 1:55:31 PM
https://www.janssen.com/compassionate-use-pre-approval-access/investigational-medicines-for-compassionate-use-requests
Investigational Medicines for Compassionate Use Requests
At Janssen, we are often asked how patients with serious diseases may potentially obtain medicines not yet approved by government health authorities (investigational medicines).
“Pre-approval access” is the term used within Janssen for any access to an investigational medicine prior to its approval.
The main pathway for patient access to Janssen’s investigational medicines is to enroll in a clinical trial. Information about ongoing Janssen clinical trials can be found at Janssen Global Trial Finder and ClinicalTrials.gov.
If a clinical trial is not available or a patient does not qualify for a clinical trial, there may be another option. A patient’s treating physician may submit an individual request for access to an investigational medicine (also known as compassionate use). Janssen reviews each such request, and makes decisions on an individual basis by evaluating factors that include but are not limited to:
The patient is not eligible or cannot participate in a clinical trial
The patient must have a serious or life-threatening disease or condition
No alternative therapies are available, or the patient must have exhausted all such therapies
Potential benefits of the investigational treatment outweigh the potential risks
Country-level laws and regulations
Availability of medication supply
While all pre-approval access requests are considered in a fair and just manner, please understand, submitting a request does not guarantee that access will be granted. To learn more about our policies and procedures please click here.
Please see the list below of Janssen investigational medicines which may be considered for pre-approval access. *This list is up-to-date as of September 4, 2018, and is subject to change.
Oncology Infectious Diseases Neuroscience Immunology
Erdafitinib JNJ-53718678 Esketamine JNJ-64304500
Imetelstat Pimodivir
CSF1R Rilpivirine
Long-Acting
For more information about the medicines listed above or any other Janssen medicine, please contact Janssen Medical Information via:
In the United States, please call 1-800-JANSSEN or email: janssenmedinfo@its.jnj.com.
Outside of the United States, please contact your Janssen local country office via our Contact Us page.
Treating physicians who wish to submit a pre-approval access request may do so by visiting the Janssen Managed Access Portal.
Recent GERN News
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/20/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:05:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/10/2024 09:53:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/10/2024 04:30:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:10:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:10:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:10:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:10:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:10:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:10:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:03:44 PM
- Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia • Business Wire • 06/07/2024 01:58:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:05:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 09:02:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 08:05:30 PM
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/16/2024 08:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2024 08:07:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:05:15 PM
- Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights • Business Wire • 05/02/2024 11:00:00 AM
- Geron to Announce First Quarter 2024 Financial Results on May 2, 2024 • Business Wire • 04/25/2024 08:30:00 PM
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/18/2024 08:30:00 PM
- Geron to Participate at Upcoming Investor Conferences in April • Business Wire • 04/03/2024 08:30:00 PM
- Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants • Business Wire • 03/19/2024 01:07:00 PM
- Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS • Business Wire • 03/14/2024 07:54:00 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM